C. Verhagen

1.2k total citations
25 papers, 875 citations indexed

About

C. Verhagen is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Clinical Biochemistry. According to data from OpenAlex, C. Verhagen has authored 25 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 5 papers in Clinical Biochemistry. Recurrent topics in C. Verhagen's work include Neutropenia and Cancer Infections (7 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Dementia and Cognitive Impairment Research (3 papers). C. Verhagen is often cited by papers focused on Neutropenia and Cancer Infections (7 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Dementia and Cognitive Impairment Research (3 papers). C. Verhagen collaborates with scholars based in Netherlands, United States and Germany. C. Verhagen's co-authors include Petra Servaes, Gijs Bleijenberg, B.E. de Pauw, Odd Erik Johansen, Geert Jan Biessels, Urban Ekman, Esther van den Berg, Andrew Simmons, Lena Cavallin and J‐Sebastian Muehlboeck and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Scientific Reports.

In The Last Decade

C. Verhagen

24 papers receiving 846 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Verhagen Netherlands 12 416 237 208 189 136 25 875
Paul Farquhar-Smith United Kingdom 15 268 0.6× 156 0.7× 104 0.5× 80 0.4× 154 1.1× 35 1.1k
Jean‐Claude Desport France 22 59 0.1× 116 0.5× 121 0.6× 254 1.3× 167 1.2× 102 1.5k
Elaine Boland United Kingdom 18 253 0.6× 166 0.7× 44 0.2× 66 0.3× 150 1.1× 42 844
Gabriella Tikellis Australia 26 49 0.1× 150 0.6× 231 1.1× 26 0.1× 185 1.4× 65 1.9k
Erin F. Carlton United States 13 67 0.2× 171 0.7× 83 0.4× 194 1.0× 41 0.3× 52 799
Webb A. Smith United States 17 230 0.6× 435 1.8× 83 0.4× 56 0.3× 224 1.6× 37 1.1k
Alejandro Álvarez‐Bustos Spain 13 172 0.4× 77 0.3× 131 0.6× 124 0.7× 80 0.6× 47 1.2k
Giulia Ogliari United Kingdom 18 65 0.2× 80 0.3× 30 0.1× 93 0.5× 67 0.5× 30 952
Anna Skalska Poland 19 68 0.2× 28 0.1× 63 0.3× 112 0.6× 89 0.7× 58 1.1k
Rongrong Yang China 17 40 0.1× 68 0.3× 53 0.3× 154 0.8× 56 0.4× 63 780

Countries citing papers authored by C. Verhagen

Since Specialization
Citations

This map shows the geographic impact of C. Verhagen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Verhagen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Verhagen more than expected).

Fields of papers citing papers by C. Verhagen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Verhagen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Verhagen. The network helps show where C. Verhagen may publish in the future.

Co-authorship network of co-authors of C. Verhagen

This figure shows the co-authorship network connecting the top 25 collaborators of C. Verhagen. A scholar is included among the top collaborators of C. Verhagen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Verhagen. C. Verhagen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Verhagen, C., et al.. (2025). Enterprise-level AI screening for oncology trials: Improving patient identification with OncoLLM.. Journal of Clinical Oncology. 43(16_suppl).
2.
Verhagen, C., Esther van den Berg, Christoph Wanner, et al.. (2022). Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk. Journal of Diabetes and its Complications. 36(10). 108303–108303. 3 indexed citations
3.
Verhagen, C., et al.. (2021). Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study. Nutrition Metabolism and Cardiovascular Diseases. 32(2). 355–364. 23 indexed citations
4.
Biessels, Geert Jan, C. Verhagen, Esther van den Berg, et al.. (2021). Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 64(6). 1235–1245. 37 indexed citations
5.
Verhagen, C., et al.. (2020). Diabetes-specific dementia risk score (DSDRS) predicts cognitive performance in patients with type 2 diabetes at high cardio-renal risk. Journal of Diabetes and its Complications. 34(10). 107674–107674. 7 indexed citations
6.
Biessels, Geert Jan, C. Verhagen, Esther van den Berg, et al.. (2019). Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care. 42(10). 1930–1938. 62 indexed citations
7.
8.
Verhagen, C., Ewald M. Bronkhorst, P.N.R. Dekhuijzen, et al.. (2017). Proactive palliative care for patients with COPD (PROLONG): a pragmatic cluster controlled trial. International Journal of COPD. Volume 12. 2795–2806. 44 indexed citations
9.
Ferreira, Daniel, C. Verhagen, Juan Hernández, et al.. (2017). Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Scientific Reports. 7(1). 46263–46263. 134 indexed citations
10.
Verhagen, C., et al.. (2017). The view of pulmonologists on palliative care for patients with COPD: a survey study. International Journal of COPD. Volume 12. 299–311. 29 indexed citations
11.
12.
Servaes, Petra, C. Verhagen, & Gijs Bleijenberg. (2002). Fatigue in cancer patients during and after treatment. European Journal of Cancer. 38(1). 27–43. 399 indexed citations
13.
Nováková, I.R.O., J. Peter Donnelly, C. Verhagen, & B.E. de Pauw. (1990). Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. Journal of Antimicrobial Chemotherapy. 25(6). 985–993. 21 indexed citations
14.
Pauw, B.E. de, et al.. (1990). Towards individually tailored empiric antibiotic therapy in febrile granulocytopenic patients.. PubMed. 37(3-4). 111–9. 11 indexed citations
15.
Verhagen, C., et al.. (1988). Ceftazidime sodium carbonate versus ceftazidime arginine as empirical monotherapy in febrile neutropenic patients. European Journal of Clinical Microbiology & Infectious Diseases. 7(2). 178–182. 2 indexed citations
16.
Pauw, B.E. de, et al.. (1988). Co-trimoxazole in patients with haematological malignancies: a review of 10-years' clinical experience. Current Medical Research and Opinion. 11(1). 64–72. 1 indexed citations
17.
Verhagen, C., Lukas J.A. Stalpers, B.E. de Pauw, & C. Haanen. (1987). Drug‐induced skin reactions in patients with acute non‐lymphocytic leukaemia. European Journal Of Haematology. 38(3). 225–230. 11 indexed citations
18.
Verhagen, C. & B.E. de Pauw. (1987). Teicoplanin for therapy of gram-positive infections in neutropenic patients.. PubMed. 7(6). 491–8. 7 indexed citations
19.
Verhagen, C., B.E. de Pauw, J. Peter Donnelly, et al.. (1986). Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. Journal of Infection. 13(2). 125–131. 12 indexed citations
20.
Verhagen, C., B.E. de Pauw, T. de Witte, et al.. (1986). Ceftazidime does not enhance cyclosporin-a nephrotoxicity in febrile bone marrow transplantation patients. Annals of Hematology. 53(4). 333–339. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Farquhar-Smith Breakdown of academic impact, for papers by Jean‐Claude Desport Breakdown of academic impact, for papers by Elaine Boland Breakdown of academic impact, for papers by Gabriella Tikellis Breakdown of academic impact, for papers by Erin F. Carlton Breakdown of academic impact, for papers by Webb A. Smith Breakdown of academic impact, for papers by Alejandro Álvarez‐Bustos Breakdown of academic impact, for papers by Giulia Ogliari Breakdown of academic impact, for papers by Anna Skalska Breakdown of academic impact, for papers by Rongrong Yang
Rankless by CCL
2026